圣达生物(603079) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 348.80% to CNY 200,406,148.72 for the first nine months of the year[6] - Operating revenue for the first nine months increased by 78.35% to CNY 666,879,888.27 compared to the same period last year[6] - Basic earnings per share reached CNY 1.19, a 325.00% increase from the previous year[7] - The weighted average return on equity improved to 16.85%, up 11.4 percentage points from the previous year[7] - The net profit increased to ¥433,106,931.26, a 75.08% rise from ¥247,374,121.78 year-on-year[12] - Total operating revenue for Q3 2020 reached ¥216,441,191.59, a 76.0% increase compared to ¥122,994,796.80 in Q3 2019[25] - Net profit for Q3 2020 was ¥47,089,756.50, representing a 450.5% increase from ¥8,541,744.68 in Q3 2019[27] - The profit before tax for Q3 2020 was ¥55,714,612.89, up from ¥11,538,743.21 in Q3 2019[26] - The company reported a total profit of ¥53.04 million in Q3 2020, compared to ¥1.57 million in Q3 2019, representing an increase of approximately 3265.5%[31] Cash Flow - Cash flow from operating activities surged by 950.43% to CNY 248,816,246.60 year-to-date[6] - The total operating cash inflow for the first three quarters of 2020 was ¥644.28 million, up from ¥415.86 million in the same period of 2019, reflecting a growth of about 55%[34] - The net cash flow from operating activities for Q3 2020 was ¥248.82 million, a significant increase from ¥23.69 million in Q3 2019, marking an increase of approximately 949.5%[35] - The cash flow from investment activities in the first three quarters of 2020 was ¥1.19 million, a recovery from a negative cash flow of ¥96.71 million in the same period of 2019[35] - The company incurred a net cash outflow from investment activities of -¥12,131,644.06 in the first three quarters of 2020, an improvement from -¥148,770,337.68 in the same period of 2019[36] - The company’s cash flow from operating activities showed a strong performance, with cash inflows significantly exceeding cash outflows, indicating robust operational efficiency[36] Assets and Liabilities - Total assets increased by 9.09% to CNY 1,671,956,148.57 compared to the end of the previous year[6] - The total amount of other receivables increased by 324.52% to ¥2,851,731.08, primarily due to increased deposits and guarantees[12] - Total liabilities decreased by 43.33% to ¥43,112,817.21, mainly due to the settlement of certain acceptances[12] - Total liabilities decreased to ¥339,814,639.68 from ¥620,880,738.09, a reduction of approximately 45.3%[19] - Total assets as of the end of Q3 2020 amounted to ¥1,472,969,396.57, an increase from ¥1,293,960,278.57 at the end of Q3 2019[23] - Total liabilities as of Q3 2020 were ¥207,295,263.39, down from ¥446,964,578.63 in Q3 2019[23] - The company’s total liabilities included short-term borrowings of ¥105,795,388.89 and accounts payable of ¥86,195,080.38 as of Q3 2020[40] - The total current liabilities included short-term borrowings of CNY 75,753,497.22 and accounts payable of CNY 18,278,225.66[45] Shareholder Information - The number of shareholders totaled 18,501 at the end of the reporting period[9] - Shareholders' equity increased to ¥1,332,141,508.89 from ¥911,708,901.40, indicating a growth of about 46.2%[20] - The company reported a total equity of ¥1,265,674,133.18 as of Q3 2020, compared to ¥846,995,699.94 in Q3 2019[23] - The company’s total equity increased by CNY 846,995,699.94, reflecting a stable financial position[46] Research and Development - Research and development expenses rose to ¥26,533,336.97, marking a 43.88% increase from ¥18,440,715.29 in the previous year[13] - Research and development expenses for Q3 2020 were ¥10,135,669.80, an increase from ¥8,277,832.20 in Q3 2019[26] - Research and development expenses for Q3 2020 were ¥5.61 million, slightly up from ¥5.54 million in Q3 2019, showing a marginal increase of about 1.3%[30] Future Plans - The company plans to continue its market expansion and product development strategies in the upcoming quarters[11] - The company plans to expand its market presence and invest in new product development to drive future growth[20] - The company has implemented new strategies to enhance operational efficiency and reduce costs, contributing to improved financial performance[20]